US drug regulator classifies Aurobindo Pharma arm's Andhra facility as 'voluntary action indicated'

Aurobindo Pharma Limited has announced that its subsidiary, Apitoria Pharma Pvt Ltd, received a VAI classification for its facility. The classification indicates that some objectionable conditions were found, but no regulatory actions will occur. ...

New Delhi: Aurobindo Pharma Limited on Saturday said its wholly-owned subsidiary, Apitoria Pharma Pvt Ltd, has received a "Voluntary Action Indicated" (VAI) classification from the US health regulator for its API manufacturing facility in Andhra Pradesh.

A 'VAI' classification means that while objectionable conditions or practices were found during the inspection, the agency is not prepared to take or recommend any administrative or regulatory action.

The United States Food and Drug Administration (USFDA) had inspected Unit-VI of Apitoria Pharma, at Anakapalli district, Andhra Pradesh, from August 24-28, 2026, and concluded with three observations, Aurobindo Pharma said in a regulatory filing.


The unit has now received the Establishment Inspection Report (EIR), classifying the facility as VAI, the company said, adding, "The USFDA has concluded that this inspection is now closed."
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › US drug regulator classifies Aurobindo Pharma arm's Andhra facility as 'voluntary action indicated'
Text Size:AAA
Success
This article has been saved

*

+